Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90089


RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to kill tumor cells. Biological therapies such as interferon gamma and interleukin-2 use different ways to stimulate the immune system and stop cancer cells from growing. Combining vaccine therapy with biological therapy may kill more tumor cells. PURPOSE: This phase II trial is studying giving vaccine therapy together with interferon gamma and interleukin-2 in treating patients with stage III or stage IV melanoma.

Study summary:

OBJECTIVES: - Determine the clinical response rate and immune response in HLA-A2 positive patients with stage III or IV melanoma after receiving autologous dendritic cells pulsed with melanoma antigen peptides (MART-1:26-35, gp100:209-217, and tyrosinase:368-376) and treated ex vivo with CD40-ligand and interferon gamma, followed by interleukin-2 in vivo. - Determine the toxicities of this regimen in these patients. OUTLINE: This is a multicenter study. Patients undergo leukapheresis to harvest autologous dendritic cells (ADCs). Melanoma peptides (MART-1:26-35, gp100:209-217, and tyrosinase:368-376) are pulsed separately onto ADCs, which are also treated ex vivo with CD40-ligand, interferon gamma, interleukin-4, sargramostim (GM-CSF), and Candida albicans skin test reagent. Patients receive each melanoma peptide pulsed ADC vaccine separately via 3 successive 10 minute infusions on day 1. Patients then receive interleukin-2 subcutaneously every 12 hours on days 2-6. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients are followed at 4 weeks, then every 3 months for 2 years, then every 6 months for 3 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 21-41 patients will be accrued for this study within 18-24 months.


DISEASE CHARACTERISTICS: - Histologically confirmed metastatic melanoma - Measurable disease after attempted curative surgery - Unresectable stage III or IV uveal melanoma - Metastatic mucosal melanoma - HLA-A2.1 positive - No disease progression following high dose interleukin-2 (600,000 or 720,000 IU/kg every 8 hours) PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-1 Life expectancy: - Not specified Hematopoietic: - WBC at least 3,000/mm^3 - Platelet count at least 75,000/mm^3 - Hemoglobin at least 9.0 g/dL - No coagulation disorders Hepatic: - Bilirubin no greater than 2.0 mg/dL Renal: - Creatinine no greater than 2.0 mg/dL Cardiovascular: - No myocardial infarction within the past 6 months - Patients with documented or suspected coronary artery disease must undergo stress thallium test - No major cardiovascular illness Pulmonary: - No major pulmonary illness Immunologic: - HIV negative - Hepatitis B surface antigen negative - Hepatitis C antibody negative - No history of uveitis or autoimmune inflammatory eye disease Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No major systemic infection - No other malignancy within the past 5 years except curatively treated carcinoma in situ of the cervix or basal cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: - See Disease Characteristics - No prior MART-1:26-35, gp100:209-217, or tyrosinase:368-376 antigens Chemotherapy: - At least 1 month since prior chemotherapy for melanoma Endocrine therapy: - No concurrent steroid therapy Radiotherapy: - At least 1 month since prior radiotherapy for melanoma Surgery: - See Disease Characteristics Other: - At least 1 month since prior adjuvant therapy for melanoma - At least 1 month since other prior therapy for melanoma



Primary Contact:

Study Chair
Jeffrey S. Weber, MD, PhD
University of Southern California

Backup Contact:


Location Contact:

Los Angeles, California 90089
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.